Ankyrin repeat domain-containing protein 29 (ANKRD29)

Ankyrin repeat domain-containing protein 29 (ANKRD29) is a protein-coding gene located on chromosome 18q11.2, encoding a protein characterized by eight ankyrin repeat motifs. Although its precise molecular functions remain to be fully dissected, current evidence demonstrates ANKRD29 acts as a tumor suppressor in NSCLC, restraining tumor cell proliferation, migration, epithelial-mesenchymal transition (EMT), and modulating drug sensitivity and immune microenvironment, primarily through regulation of the MAPK signaling pathway. Downregulation of ANKRD29 in NSCLC frequently results from promoter hypermethylation, which is associated with adverse patient prognosis. Recent studies identify ANKRD29 as both a prognostic and immunological biomarker, with expression levels correlated to overall survival and therapeutic response, as well as a candidate molecular target for cancer therapy. Evidence for direct interaction with drugs (BEZ235, AKT inhibitor VIII) is emerging from molecular docking studies, though pharmacologic targeting is still experimental. Additionally, the function and phenotype contributions of ANKRD29 have been linked to genetic disorders (e.g., Niemann–Pick type C disease when deleted alongside NPC1), demonstrating its dual relevance in inherited and acquired pathologies.

Other names

Ankyrin repeat domain-containing protein 29ANKRD29FLJ25053ANR29 (protein)

Activation/agonism: BEZ235 and AKT inhibitor VIII were identified as potential agonists for ANKRD29 in specific molecular docking screens. Epigenetic modulation: Methyltransferase inhibitors (e.g., 5-Aza) increase ANKRD29 expression by demethylating the promoter. Enhanced drug sensitivity: Overexpression increases sensitivity to cytotoxic agents (e.g., carboplatin).